Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world retrospective study of rezvilutamide plus ADT in mHSPC
ChiCTR2500115647Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rezvilutamide in prostate cancer (PCa), sponsored by First Affiliated Hospital of Ningbo University. Primary endpoints: PSA response rate at 6 months, Time to PSA progression and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2500115647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115647.